Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that
stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with
increasing incidence worldwide. Crohn's disease might result from a complex interplay …

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and
adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis …

Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern …

Crohn's disease is a chronic inflammatory, relapsing-remitting, and progressive
gastrointestinal disorder with an often-negative impact on the physical, emotional, and …

Background and Aims: A biosimilar version of infliximab [CT-P13/Remsima®] recently
entered the European market. The clinical data on its use in inflammatory bowel disease …

Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab
pegol and golimumab, have been proven to be effective for the treatment of patients with …

Abstract Introduction Inflammatory bowel diseases (IBDs) are a public health issue with over
3.5 million patients in Europe, but the advent of several biologic agents has completely …